Table of Contents Author Guidelines Submit a Manuscript
Bioinorganic Chemistry and Applications
Volume 2010, Article ID 183097, 6 pages
http://dx.doi.org/10.1155/2010/183097
Research Article

Synthesis and Characterization of Novel Ruthenium(III) Complexes with Histamine

1Faculty of Chemistry and Chemical Technology, University of Ljubljana, Aškerčeva 5, 1000 Ljubljana, Slovenia
2Department of Environmental Sciences, Jožef Stefan Institute, Jamova c. 39, 1000 Ljubljana, Slovenia
3Faculty of Electrical Engeneering, University of Ljubljana, Tržaška 25, 1000 Ljubljana, Slovenia

Received 30 December 2009; Accepted 9 March 2010

Academic Editor: Spyros Perlepes

Copyright © 2010 Jakob Kljun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Wiltshaw, “Cisplatin in the treatment of cancer: the first metal anti-tumour drug,” Platinum Metals Review, vol. 23, no. 3, pp. 90–98, 1979. View at Google Scholar · View at Scopus
  2. L. Kelland, “The resurgence of platinum-based cancer chemotherapy,” Nature Reviews Cancer, vol. 7, no. 8, pp. 573–584, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. T. W. Hambley, “Developing new metal-based therapeutics: challenges and opportunities,” Dalton Transactions, no. 43, pp. 4929–4937, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Alessio, G. Mestroni, A. Bergamo, and G. Sava, “Ruthenium antimetastatic agents,” Current Topics in Medicinal Chemistry, vol. 4, no. 15, pp. 1525–1535, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. C. G. Hartinger, S. Zorbas-Seifried, M. A. Jakupec, B. Kynast, H. Zorbas, and B. K. Keppler, “From bench to bedside—preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A),” Journal of Inorganic Biochemistry, vol. 100, no. 5-6, pp. 891–904, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. C. G. Hartinger, M. A. Jakupec, S. Zorbas-Seifried et al., “KP1019, a new redox-active anticancer agent—preclinical development and results of a clinical phase I study in tumor patients,” Chemistry and Biodiversity, vol. 5, no. 10, pp. 2140–2155, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Reisner, V. B. Arion, A. Eichinger et al., “Tuning of redox properties for the design of ruthenium anticancer drugs—part 2: syntheses, crystal structures, and electrochemistry of potentially antitumor [RuIII/IICl6-n(Azole)n]z (n=3, 4, 6) complexes,” Inorganic Chemistry, vol. 44, no. 19, pp. 6704–6716, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. I. Bratsos, S. Jedner, T. Gianferrara, and E. Alessio, “Ruthenium anticancer compounds: challenges and expectations,” Chimia, vol. 61, no. 11, pp. 692–697, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. E. H. Serpersu, K. Kinosita Jr., and T. Y. Tsong, “Reversible and irreversible modification of erythrocyte membrane permeability by electric field,” Biochimica et Biophysica Acta, vol. 812, no. 3, pp. 779–785, 1985. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Teissie, M. Golzio, and M. P. Rols, “Mechanisms of cell membrane electropermeabilization: a minireview of our present (lack of ?) knowledge,” Biochimica et Biophysica Acta, vol. 1724, no. 3, pp. 270–280, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Pavlin and D. Miklavčič, “Theoretical and experimental analysis of conductivity, ion diffusion and molecular transport during cell electroporation–relation between short-lived and long-lived pores,” Bioelectrochemistry, vol. 74, no. 1, pp. 38–46, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Orlowski, J. Belehradek Jr., C. Paoletti, and L. M. Mir, “Transient electropermeabilization of cells in culture: increase of the cytotoxicity of anticancer drugs,” Biochemical Pharmacology, vol. 37, no. 24, pp. 4727–4733, 1988. View at Google Scholar · View at Scopus
  13. G. Serša, M. Čemažar, and D. Miklavčič, “Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice,” Cancer Research, vol. 55, no. 15, pp. 3450–3455, 1995. View at Google Scholar · View at Scopus
  14. Z. Otwinowski and W. Minor, “Processing of X-ray diffraction data collected in oscillation mode,” Methods in Enzymology, vol. 276, pp. 307–326, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Altomare, M. C. Burla, M. Camalli et al., “SIR97: a new tool for crystal structure determination and refinement,” Journal of Applied Crystallography, vol. 32, no. 1, pp. 115–119, 1999. View at Google Scholar · View at Scopus
  16. G. M. Sheldrick, “A short history of SHELX,” Acta Crystallographica Section A, vol. 64, no. 1, pp. 112–122, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. C. F. Macrae, P. R. Edgington, P. McCabe et al., “Mercury: visualization and analysis of crystal structures,” Journal of Applied Crystallography, vol. 39, no. 3, pp. 453–457, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Alessio, G. Balducci, M. Calligaris, G. Costa, W. M. Attia, and G. Mestroni, “Synthesis, molecular structure, and chemical behavior of hydrogen trans-bis(dimethyl sulfoxide)tetrachlororuthenate(III) and mer-trichlorotris(dimethyl sulfoxide)ruthenium(III): the first fully characterized chloride-dimethyl sulfoxide-ruthenium(III) complexes,” Inorganic Chemistry, vol. 30, no. 4, pp. 609–618, 1991. View at Google Scholar · View at Scopus
  19. D. Griffith, S. Cecco, E. Zangrando, A. Bergamo, G. Sava, and C. J. Marmion, “Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation,” Journal of Biological Inorganic Chemistry, vol. 13, no. 4, pp. 511–520, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. I. Turel, M. Pecanac, A. Golobic et al., “Solution, solid state and biological characterization of ruthenium(III)-DMSO complexes with purine base derivatives,” Journal of Inorganic Biochemistry, vol. 98, no. 2, pp. 393–401, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. A. García-Raso, J. J. Fiol, A. Tasada et al., “Ruthenium complexes with purine derivatives: syntheses, structural characterization and preliminary studies with plasmidic DNA,” Inorganic Chemistry Communication, vol. 8, no. 9, pp. 800–804, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Alessio, G. Balducci, A. Lutman, G. Mestroni, M. Calligaris, and W. M. Attia, “Synthesis and characterization of two new classes of ruthenium(III)-sulfoxide complexes with nitrogen donor ligands (L): Na[trans-RuCl4(R2SO)(L)] and mer, cis-RuCl3(R2SO)(R2SO)(L). The crystal structure of Na[trans-RuCl4(DMSO)(NH3)] ·2DMSO, Na[trans-RuCl4(DMSO)(Im)] ·H2O, Me2CO (Im = imidazole) and mer, cis-RuCl3(DMSO)(DMSO)(NH3),” Inorganica Chimica Acta, vol. 203, no. 2, pp. 205–217, 1993. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Mestroni, E. Alessio, G. Sava, S. Pacor, M. Coluccia, and A. Boccarelli, “Water-soluble ruthenium(III)-dimethyl sulfoxide complexes: chemical behaviour and pharmaceutical properties,” Metal-Based Drugs, vol. 1, no. 1, pp. 41–63, 1993. View at Google Scholar
  24. A. Bicek, I. Turel, M. Kanduser, and D. Miklavcic, “Combined therapy of the antimetastatic compound NAMI-A and electroporation on B16F1 tumour cells in vitro,” Bioelectrochemistry, vol. 71, no. 2, pp. 113–117, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. P. J. Dyson and G. Sava, “Metal-based antitumour drugs in the post genomic era,” Dalton Transactions, no. 16, pp. 1929–1933, 2006. View at Publisher · View at Google Scholar · View at Scopus